Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Latest Information Update: 15 May 2024
At a glance
- Drugs Posaconazole (Primary)
- Indications Glioma
- Focus Pharmacokinetics
- 08 May 2024 Planned End Date changed from 1 May 2024 to 1 Jan 2025.
- 08 May 2024 Planned primary completion date changed from 1 May 2024 to 1 Dec 2024.
- 06 Feb 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.